New features of pertussis vaccination
https://doi.org/10.22627/2072-8107-2020-19-2-58-63
Abstract
The review provides information about the current features of the spread of whooping cough among children and adolescents. It is shown that there is a shift in morbidity to an older age group of the population, which is facilitated by changes in the properties of the pathogen and the widespread use of drugs based on cell-free technology as primary vaccination. Information is given about the possibility of preventing morbidity among schoolchildren and adults by introducing additional revaccinating doses against whooping cough with special drugs in the vaccination calendars. Information is given on effective protection of newborns against this infection by immunization of pregnant women. In our country, there is an opportunity to expand pertussis immunoprophylaxis among children of preschool-school age and adults within regional programs and individual vaccination with acellular pertussis-diphtheria-tetanus vaccines, which has a high profile of safety and immunological effectiveness.
About the Authors
A. P. Cherdantsev
Ulyanovsk State University
Russian Federation
МD, Professor of the Department of Pediatrics, Institute of Medicine, Ecology and Physical Culture
Russian Federation
МD, Professor of the Department of Pediatrics, Institute of Medicine, Ecology and Physical Culture
E. V. Prutskova
Ulyanovsk State University
Russian Federation
Ekaterina Prutskova
Russian Federation
Ekaterina Prutskova
M. P. Kostinov
I.I. Mechnikov Research Institute for Vaccines and Sera; Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Michail Kostinov, MD, professor
Moscow
References
1. Edwards K.M., Decker M.D. Pertussis vaccines. In: Plotkin S., Orenstein W., Offit P., eds. Vaccines, 6th ed. Philadelphia, Saunders, 2013:447—492.
2. Pertussis vaccines: WHO pertussis position paper — August 2015. WeeklyEpidemiolRec 2015; 90:433—460. URL: http://www.who.int/wer/2015/wer9035.pdf
3. Report from the SAGE Working Group on Pertussis vaccines, 26— 27 August 2014 meeting, Geneva, Switzerland. Available at http://www.who.int/immunization/sage/meetings/2015/april/ 1_Pertussis_report_final.pdf?ua=1
4. Brenzel L., Wolfson L.J., Fox-Rushby J., Miller M., Halsey N.A. Vaccine preventable diseases. In: Jamison D.T., Breman J.G., Measham A.R. et al. eds. Disease control priorities in developing countries. 2nd ed. New York, Oxford University Press, 2006:389—412.
5. Global Health Observatory Data Repository. Available at http://apps.who.int/gho/data/node.main.ChildMortREG100?lang=en; accessed July 2015
6. Зайцев Е.М. Эпидемический процесс и вакцинопрофилактика коклюша. Журнал микробиологии, эпидемиологии и иммунобиологии. 2013; 3: 103—105. [Zaitsev E.M. Epidemic process and vaccine prophylaxis of pertussis. Journal of Microbiology, Epidemiology and Immunobiology. 2013; 3: 103—105. (In Russ.)]
7. Wright S.W., Edwards K.M., Decker M., Zeldin MHl. Pertussis infection in adults with persistent cough. Journal of the American Medical Association, 1995, 273:1044—1046.
8. Wiley K.E., Zuo Y., Macartney K.K., McIntyre P.B. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine, 2013; 31:618—625.
9. Njamkepo E., Rimlinger F., Thiberge S., Guiso N. Thirty-5 years’ experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine, 2002, 20:1290— 1294.
10. Hegerle N., Guiso N. Epidemiology of whooping cough & typing of Bordetella pertussis. (Report). Future Microbiology, 2013; 8(11): 1391.
11. Hegerle N., Dore G., Guiso N. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine. Vaccine, 2014; 32(49):6597—6600.
12. Martin S.W., Pawloski L., Williams M., Weening K., DeBolt C., Qin X, et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. (Report). Clinical Infectious Diseases, 2015; 60(2):223.
13. Ивашинникова Г.А., Борисова О.Ю., Гадуа Н.Т. и др. Характеристика современных штаммов B. pertussis по структуре ptxP гена, кодирующего промоторную область коклюшного токсина. Инфекционные болезни: прил. 2012: 161. [Ivashinnikova G.A., Borisova O.Yu., Gadua N.T. i dr. Characterization of modern B. pertussis strains according to the ptxP standard of a gene encoding the promoter region of pertussis toxasin. Infectious Diseases: adj.2012: 161. (In Russ.)]
14. Hegerle N., Guiso N. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines. Expert Review of Vaccines, 2014;13(9):1135.
15. Mooi F.R., He Q., Guiso N. Phylogeny, evolution and epidemiology of Bordetellae. In: Locht C, ed. Bordetella: molecular microbiology. Norfolk, England, Horizon Biosciences, 2007: 17—46.
16. Wirsing von König C.H. The immunological basis for immunization series: module 4: pertussis — update 2009. Geneva: World Health Organization, 2010, pp.50.
17. Wearing H.J., Rohani P. Estimating the duration of pertussis using immunity epidemiological signatures. PLoS Pathogens. 2009. DOI: 10.1371/journal.ppat.1000647
18. Костинов А.М., Костинов М.П. Заболеваемость коклюшем и эффект от ревакцинации детей дошкольного и школьного возраста. Инфекция и иммунитет. 2018. 8(3): 284—294. [Kostinov А.M., Kostinov M.P. Pertussis incidence and the effect of revaccination of preschool and school children. Russian Journal of Infection and Immunity. 2018; 8(3):284—294. (In Russ.) doi.org/10.15789/2220-7619-2018-3-284-294]
19. Amirthalingam G., Andrews N., Campbell H., Ribeiro S., Kara E., Donegan K., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet, 2014 Oct 25; 384(9953): 1521—1528.
20. Шмитько А.Д., Новикова С.В., Бочарова И.И., Якубина А.А., Костинов М.П. Механизмы и факторы, влияющие на трансплацентарную передачу IgG-антител в системе мать-плацента-плод. Российский вестник акушера-гинеколога, 2014. 14(6): 27—31. [Shmit`ko A.D., Novikova S.V., Bocharova I.I., Yakubina A.A., Kostinov M.P. Mechanisms and factors affecting transplacental transmission of IgG antibodies in the mother-placenta-fetus system. Russian Bulletin of the Obstetrician-Gynecologist, 2014. 14(6):27— 31. (In Russ.)]
21. WHO SAGE pertussis working group. Background paper. SAGE April 2014. Available at http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINAL4_web.pdf?ua=; accessed July 2015
22. Петина О.А. Большакова Л.Н. Лешкевич И.А. Костинов М.П. Оценка безопасности вакцинации детей комбинированными препаратами, содержащими цельноклеточную или бесклеточную коклюшную вакцину. Эпидемиология и инфекционные болезни. Актуальные вопросы, 2015. 3: 44—49. [Petina O.A. Bol`shakova L.N. Leshkevich I.A. Kostinov M.P. Safety assessment of vaccination of children with combined preparations containing whole cell or acellular pertussis vaccine . Epidemiology and Infectious Diseases. Actual issues, 2015. 3: 44—49. (In Russ.)]
23. Костинов М.П., Андреева Н.П., Черданцев А.П. Сравнительный анализ клинической безопасности вакцин, содержащих цельноклеточные и ацеллюлярные коклюшные компоненты. Инфекционные болезни. 2018. 7(2): 92—97. [Kostinov M.P., Andreeva N.P., Cherdanczev A.P. Comparative analysis of the clinical safety of vaccines containing whole cell and acellular pertussis components. Infectious diseases. 2018. 7(2): 92—97. (In Russ.) doi.org/10/24411/2305-3496-2018-12011]
24. Тарасова А.А., Лукушкина Е.Ф., Костинов М.П. и др. Вакцинопрофилактика. Учебно-методическое пособие. Н. Новгород: Издательский салон И.П. Гладкова, 2016:103. [Tarasova A.A., Lukushkina E.F., Kostinov M.P. i dr. Vaccine prophylaxis. Teaching aid. N. Novgorod: Publishing Salon I.P. Gladkova, 2016: 103. (In Russ.)]
25. King G.E., Hadler S.C. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J. 1994; 13:394—407.
26. Dolan S., Wallace A., Burnett E., Ehlman D., Sui W., Garon J., Patel M., Hampton L., Kay A., Chmielewski E., and Hyde T. Summary of evidence on the administration of multiple injectable vaccines in infants during a single visit: safety, immunogenicity, and vaccine administration practices (prepared for the April 2015 SAGE meeting. Available at http://www.who.int/immunization/sage/meetings/2015/april/5_Summary_of_Evidence_3-25-2015.pdf?ua=1; accessed July 2015.
27. Edwards K.E., Decker M.D. Chapter 23: Pertussis vaccines. In Vaccines, 6th ed. (Eds. Plotkin S.A., Orenstein W.A., Offit P.A.). 2013. UK: Elsevier Saunders. p.464.
28. Инструкция по применению лекарственного препарата для медицинского применения АДАСЕЛЬ (Вакцина для профилактики дифтерии (с уменьшенным содержанием антигена), столбняка и коклюша (бесклеточная), комбинированная, адсорбированная). [Instructions for use of the drug for medical use ADASEL (Vaccine for the prevention of diphtheria (with a reduced content of antigen), tetanus and pertussis (cell-free), combined, adsorbed) (In Russ.)]
29. Purdy K.W., Hay J.W., Botteman M.F., Ward J.I. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost benefit analysis. Clin. Infect. Dis. 2004; 39: 20—28. dx.doi.org/10.1086/421091
30. Thierry Carstensen B., Jordan K., Uhlving H.H. et al. A randomised, double blind, noninferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Vaccine. 2012; 30:5464—5471. dx.doi.org/10.1016/j.vaccine.2012.06.073
31. Согласованное мнение экспертов VIII Образовательного международного Консенсуса по респираторной медицине в педиатрии по вопросам организации вакцинации против коклюша г. Калуга, 19 января 2019 г. [The agreed opinion of the experts of the VIII Educational International Consensus on Respiratory Medicine in Pediatrics on the organization of vaccination against pertussis in Kaluga, January 19, 2019. (In Russ.)] http://pulmodeti.ru/wp-content/uploads/VIII_kok.pdf
32. Sheridan S.L., Frith K., Snelling T.L., Grimwood K., McIntyre P.B., Lambert S.B. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Rev Vaccines. 2014 Sep; 13(9):1081—106. doi: 10.1586/14760584.2014.944167
33. Donegan K., King B., Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ, 2014; 349:g4219.
34. Warfel J.M., Papin J.F., Wolf R.F., Zimmerman L.I., Merkel T.J. Maternal and neonatal vaccination protects newborn baboons from pertussis infection. J Infect Dis, 2014 Aug 15; 210(4):604—610.
35. Вакцинация беременных против гриппа и других инфекционных заболеваний: Руководство для врачей. А.П. Черданцев, М.П. Костинов, А.И. Кусельман (издание 3-е, дополненное). М.: Группа МДВ, 2018: 143. [Vaccination of pregnant women against influenza and other infectious diseases: a Guide for doctors. A.P. Cherdantsev, M.P. Kostinov, A.I. Kuselman (3rd edition, supplemented). M.: MDV Group, 2018: 143. (In Russ.)]
36. WHO SAGE pertussis working group. Background paper. SAGE April 2014. Available at http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINAL4_web.pdf?ua=; accessed July 2015.
37. Quinn H.E., Snelling T.L., Habig A., Chiu C., Spokes P.J., Mcintyre P.B. Parental Tdap boosters and infant pertussis: a case-control study. Pediatrics, 2014; 134(4):713.
38. Healy C.M., Rench M.A., Wootton S.H., Castagnini L.A. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J, 2015; 34(1):22.
39. Tdap Vaccine What You Need to Know. https://www.cdc.gov/vaccines/hcp/vis/vis-statements/tdap.pdf
40. Pesek R., Lockey R. Vaccination of adults with asthma and COPD. Allergy, 2011; 66:25—31.
Review
For citations:
Cherdantsev A.P., Prutskova E.V., Kostinov M.P. New features of pertussis vaccination. CHILDREN INFECTIONS. 2020;19(2):58-63. (In Russ.) https://doi.org/10.22627/2072-8107-2020-19-2-58-63
Views:
922
Email this article 